{"id":"https://openalex.org/W2931451269","doi":null,"title":"Cost-effectiveness analysis of Enzalutamide, Abiraterone acetate plus prednisone, Cabazitaxel plus prednisone for the treatment of visceral metastatic Castration Resistant Prostate Cancer (mCRPC) after Docetaxel therapy","display_name":"Cost-effectiveness analysis of Enzalutamide, Abiraterone acetate plus prednisone, Cabazitaxel plus prednisone for the treatment of visceral metastatic Castration Resistant Prostate Cancer (mCRPC) after Docetaxel therapy","publication_year":2018,"publication_date":"2018-01-01","ids":{"openalex":"https://openalex.org/W2931451269","mag":"2931451269"},"language":"en","primary_location":{"id":"pmh:oai:digitalrepository.unm.edu:skc-1204","doi":null,"is_oa":true,"landing_page_url":"https://digitalrepository.unm.edu/skc/2018/posters/5","pdf_url":"https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1204&context=skc","source":{"id":"https://openalex.org/S4377196368","display_name":"UNM\u2019s Digital Repository (University of New Mexico)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169521973","host_organization_name":"University of New Mexico","host_organization_lineage":["https://openalex.org/I169521973"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Shared Knowledge Conference","raw_type":"text"},"volume":null,"type":"conference-paper","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1204&context=skc","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065537882","display_name":"Yazan K. Barqawi","orcid":"https://orcid.org/0000-0002-3045-6813","observed_orcids":["https://orcid.org/0000-0002-3045-6813"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Yazan K. Barqawi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5065537882"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.7958999872207642,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.7958999872207642,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.15729999542236328,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.017400000244379044,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.777999997138977},{"id":"https://openalex.org/keywords/visceral-metastasis","display_name":"visceral metastases","score":0.7400000095367432},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.7670000195503235},{"id":"https://openalex.org/keywords/enzalutamide","display_name":"enzalutamide","score":0.9049999713897705},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9120000004768372},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8389999866485596},{"id":"https://openalex.org/keywords/life-years-gained","display_name":"life-years gained","score":0.7379999756813049},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.7979999780654907},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7960000038146973},{"id":"https://openalex.org/keywords/healthcare-payer-perspective","display_name":"healthcare payer perspective","score":0.6549999713897705}],"concepts":[{"id":"https://openalex.org/C2776551883","wikidata":"https://www.wikidata.org/wiki/Q1996756","display_name":"Enzalutamide","level":5,"score":0.9600774645805359},{"id":"https://openalex.org/C2778971682","wikidata":"https://www.wikidata.org/wiki/Q412963","display_name":"Cabazitaxel","level":5,"score":0.9259132146835327},{"id":"https://openalex.org/C2775832370","wikidata":"https://www.wikidata.org/wiki/Q27888393","display_name":"Abiraterone acetate","level":5,"score":0.8870570659637451},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.8730437755584717},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8364773392677307},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.8268898725509644},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8073985576629639},{"id":"https://openalex.org/C2776421732","wikidata":"https://www.wikidata.org/wiki/Q27888393","display_name":"Abiraterone","level":5,"score":0.6357627511024475},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5630560517311096},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4624175727367401},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38921910524368286},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3632034361362457},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.2706626355648041},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.10466930270195007}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:digitalrepository.unm.edu:skc-1204","doi":null,"is_oa":true,"landing_page_url":"https://digitalrepository.unm.edu/skc/2018/posters/5","pdf_url":"https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1204&context=skc","source":{"id":"https://openalex.org/S4377196368","display_name":"UNM\u2019s Digital Repository (University of New Mexico)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169521973","host_organization_name":"University of New Mexico","host_organization_lineage":["https://openalex.org/I169521973"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Shared Knowledge Conference","raw_type":"text"},{"id":"mag:2931451269","doi":null,"is_oa":false,"landing_page_url":"https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1204&context=skc","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:digitalrepository.unm.edu:skc-1204","doi":null,"is_oa":true,"landing_page_url":"https://digitalrepository.unm.edu/skc/2018/posters/5","pdf_url":"https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1204&context=skc","source":{"id":"https://openalex.org/S4377196368","display_name":"UNM\u2019s Digital Repository (University of New Mexico)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169521973","host_organization_name":"University of New Mexico","host_organization_lineage":["https://openalex.org/I169521973"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Shared Knowledge Conference","raw_type":"text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2931451269.pdf","grobid_xml":"https://content.openalex.org/works/W2931451269.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2961844706","https://openalex.org/W2953452094","https://openalex.org/W2970590492","https://openalex.org/W2103633761","https://openalex.org/W2024758584","https://openalex.org/W2079874793","https://openalex.org/W3118745137","https://openalex.org/W3085148895","https://openalex.org/W4380150059","https://openalex.org/W7099007965"],"abstract_inverted_index":{"Background:":[0],"Prostate":[1],"cancer":[2,12,29,43],"is":[3,265,288],"the":[4,16,45,114,143],"second":[5],"leading":[6],"cause":[7],"of":[8,62,132,145,161,195],"death":[9],"after":[10],"lung":[11],"among":[13],"men":[14],"in":[15,31,44,186],"US.":[17],"The":[18],"America":[19],"Cancer":[20,85],"Society":[21],"predicts":[22],"164,690":[23],"new":[24],"cases":[25],"and":[26,47,109,122,148,176,204,220,230,233,239,258,273,291],"29,430":[27],"prostate":[28,42],"deaths":[30],"2018.":[32],"In":[33,282],"2014,":[34],"nearly":[35],"US":[36,46,51,70,279],"$13.4":[37],"billion":[38,53],"was":[39,99,139,212,243],"spent":[40],"on":[41],"expected":[48,183],"to":[49,89,112,141,184,214,224,252,268,295],"reach":[50],"$15.4":[52],"by":[54,105],"2020.":[55],"Objective:":[56],"To":[57],"conduct":[58],"a":[59,69,278],"cost-effective":[60,266],"analysis":[61,138,147],"visceral":[63,91,133],"mCRPC":[64,92,134],"therapies":[65],"post-docetaxel":[66,93],"failure":[67],"from":[68,277],"healthcare":[71,280],"payer":[72],"perspective":[73],"utilizing":[74],"life-time":[75],"horizon":[76],"Markov":[77],"model.":[78],"These":[79],"medications":[80],"received":[81],"highest":[82],"National":[83],"Comprehensive":[84],"Network":[86],"guideline":[87],"recommendation":[88],"treat":[90],"failure.":[94],"Methods:":[95],"A":[96],"pharmacoeconomic":[97],"model":[98],"constructed":[100],"using":[101],"Microsoft":[102],"Excel\u00ae":[103],"supported":[104],"visual":[106],"basic":[107],"codes":[108],"macros":[110],"functions":[111],"estimate":[113],"cost-effectiveness":[115,150],"[cost":[116,125],"per":[117,126],"Life":[118,129],"Year":[119,130],"Gained":[120],"(LYG)]":[121],"cost-utility":[123],"analyses":[124],"Quality":[127],"Adjusted":[128],"(QALY)]":[131],"therapies.":[135],"Probabilistic":[136],"sensitivity":[137],"conducted":[140],"assess":[142],"robustness":[144],"base-case":[146],"provide":[149],"acceptability":[151],"curve":[152],"at":[153],"various":[154],"willingness-to-pay":[155],"thresholds.":[156],"Results:":[157],"About":[158],"(98.7":[159],"%)":[160,170,178,194,203],"patients":[162],"who":[163,171,179],"receive":[164,172,180],"abiraterone":[165,205,225,253,269,284],"acetate":[166,206,254,270,285],"plus":[167,174,200,207,226,235,255,260,271,275,286,297],"prednisone,":[168],"(83.8":[169],"cabazitaxel":[173,199,234,259,274,296],"prednisone":[175,201,208,227,236,256,261,272,276,287],"(86.8":[177],"enzalutamide":[181],"are":[182],"die":[185],"3":[187],"years.":[188],"Enzalutamide":[189,211,242,264],"provided":[190],"higher":[191],"rates":[192],"(36.1":[193],"progression-free":[196],"survival":[197],"than":[198],"(3.2":[202],"(12.8":[209],"%).":[210],"found":[213],"be":[215],"more":[216],"effective":[217,290],"(1.58":[218],"LYG":[219,229,238],"0.79":[221],"QALY)":[222,232],"compared":[223,251,267,294],"(1.20":[228],"0.58":[231],"(1.48":[237],"0.56":[240],"QALY).":[241],"also":[244],"associated":[245],"with":[246],"lower":[247],"incremental":[248],"costs":[249],"($157,830)":[250],"($235,853)":[257],"($496,756).":[262],"Conclusion:":[263],"perspective.":[281],"addition,":[283],"less":[289,292],"costly":[293],"prednisone.":[298]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-04-11T00:00:00"}